PMID- 25366685
OWN - NLM
STAT- MEDLINE
DCOM- 20150316
LR  - 20220409
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 33
IP  - 3
DP  - 2015 Jan 20
TI  - Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 
      mutation.
PG  - 244-50
LID - 10.1200/JCO.2014.56.2728 [doi]
AB  - PURPOSE: Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity 
      in germline BRCA1 and BRCA2 (BRCA1/2) -associated breast and ovarian cancers. We 
      evaluated the efficacy and safety of olaparib in a spectrum of BRCA1/2-associated 
      cancers. PATIENTS AND METHODS: This multicenter phase II study enrolled 
      individuals with a germline BRCA1/2 mutation and recurrent cancer. Eligibility 
      included ovarian cancer resistant to prior platinum; breast cancer with >/= three 
      chemotherapy regimens for metastatic disease; pancreatic cancer with prior 
      gemcitabine treatment; or prostate cancer with progression on hormonal and one 
      systemic therapy. Olaparib was administered at 400 mg twice per day. The primary 
      efficacy end point was tumor response rate. RESULTS: A total of 298 patients 
      received treatment and were evaluable. The tumor response rate was 26.2% (78 of 
      298; 95% CI, 21.3 to 31.6) overall and 31.1% (60 of 193; 95% CI, 24.6 to 38.1), 
      12.9% (eight of 62; 95% CI, 5.7 to 23.9), 21.7% (five of 23; 95% CI, 7.5 to 
      43.7), and 50.0% (four of eight; 95% CI, 15.7 to 84.3) in ovarian, breast, 
      pancreatic, and prostate cancers, respectively. Stable disease >/= 8 weeks was 
      observed in 42% of patients (95% CI, 36.0 to 47.4), including 40% (95% CI, 33.4 
      to 47.7), 47% (95% CI, 34.0 to 59.9), 35% (95% CI, 16.4 to 57.3), and 25% (95% 
      CI, 3.2 to 65.1) of those with ovarian, breast, pancreatic, or prostate cancer, 
      respectively. The most common adverse events (AEs) were fatigue, nausea, and 
      vomiting. Grade >/= 3 AEs were reported for 54% of patients; anemia was the most 
      common (17%). CONCLUSION: Responses to olaparib were observed across different 
      tumor types associated with germline BRCA1/2 mutations. Olaparib warrants further 
      investigation in confirmatory studies.
CI  - (c) 2014 by American Society of Clinical Oncology.
FAU - Kaufman, Bella
AU  - Kaufman B
AD  - Bella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; 
      Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana 
      Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, 
      Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute 
      of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; 
      Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of 
      Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer 
      Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, 
      University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter 
      MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; 
      Judith Balmana, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas 
      Loman, Skanes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra 
      Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser 
      Research Center and Abramson Cancer Center, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Shapira-Frommer, Ronnie
AU  - Shapira-Frommer R
AD  - Bella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; 
      Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana 
      Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, 
      Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute 
      of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; 
      Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of 
      Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer 
      Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, 
      University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter 
      MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; 
      Judith Balmana, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas 
      Loman, Skanes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra 
      Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser 
      Research Center and Abramson Cancer Center, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Schmutzler, Rita K
AU  - Schmutzler RK
AD  - Bella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; 
      Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana 
      Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, 
      Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute 
      of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; 
      Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of 
      Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer 
      Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, 
      University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter 
      MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; 
      Judith Balmana, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas 
      Loman, Skanes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra 
      Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser 
      Research Center and Abramson Cancer Center, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Audeh, M William
AU  - Audeh MW
AD  - Bella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; 
      Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana 
      Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, 
      Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute 
      of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; 
      Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of 
      Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer 
      Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, 
      University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter 
      MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; 
      Judith Balmana, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas 
      Loman, Skanes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra 
      Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser 
      Research Center and Abramson Cancer Center, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Friedlander, Michael
AU  - Friedlander M
AD  - Bella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; 
      Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana 
      Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, 
      Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute 
      of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; 
      Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of 
      Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer 
      Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, 
      University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter 
      MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; 
      Judith Balmana, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas 
      Loman, Skanes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra 
      Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser 
      Research Center and Abramson Cancer Center, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Balmana, Judith
AU  - Balmana J
AD  - Bella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; 
      Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana 
      Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, 
      Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute 
      of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; 
      Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of 
      Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer 
      Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, 
      University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter 
      MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; 
      Judith Balmana, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas 
      Loman, Skanes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra 
      Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser 
      Research Center and Abramson Cancer Center, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Mitchell, Gillian
AU  - Mitchell G
AD  - Bella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; 
      Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana 
      Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, 
      Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute 
      of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; 
      Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of 
      Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer 
      Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, 
      University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter 
      MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; 
      Judith Balmana, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas 
      Loman, Skanes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra 
      Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser 
      Research Center and Abramson Cancer Center, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Fried, Georgeta
AU  - Fried G
AD  - Bella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; 
      Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana 
      Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, 
      Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute 
      of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; 
      Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of 
      Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer 
      Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, 
      University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter 
      MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; 
      Judith Balmana, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas 
      Loman, Skanes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra 
      Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser 
      Research Center and Abramson Cancer Center, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Stemmer, Salomon M
AU  - Stemmer SM
AD  - Bella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; 
      Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana 
      Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, 
      Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute 
      of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; 
      Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of 
      Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer 
      Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, 
      University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter 
      MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; 
      Judith Balmana, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas 
      Loman, Skanes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra 
      Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser 
      Research Center and Abramson Cancer Center, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Hubert, Ayala
AU  - Hubert A
AD  - Bella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; 
      Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana 
      Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, 
      Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute 
      of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; 
      Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of 
      Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer 
      Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, 
      University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter 
      MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; 
      Judith Balmana, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas 
      Loman, Skanes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra 
      Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser 
      Research Center and Abramson Cancer Center, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Rosengarten, Ora
AU  - Rosengarten O
AD  - Bella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; 
      Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana 
      Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, 
      Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute 
      of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; 
      Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of 
      Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer 
      Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, 
      University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter 
      MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; 
      Judith Balmana, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas 
      Loman, Skanes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra 
      Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser 
      Research Center and Abramson Cancer Center, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Steiner, Mariana
AU  - Steiner M
AD  - Bella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; 
      Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana 
      Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, 
      Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute 
      of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; 
      Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of 
      Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer 
      Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, 
      University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter 
      MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; 
      Judith Balmana, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas 
      Loman, Skanes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra 
      Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser 
      Research Center and Abramson Cancer Center, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Loman, Niklas
AU  - Loman N
AD  - Bella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; 
      Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana 
      Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, 
      Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute 
      of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; 
      Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of 
      Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer 
      Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, 
      University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter 
      MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; 
      Judith Balmana, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas 
      Loman, Skanes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra 
      Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser 
      Research Center and Abramson Cancer Center, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Bowen, Karin
AU  - Bowen K
AD  - Bella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; 
      Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana 
      Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, 
      Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute 
      of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; 
      Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of 
      Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer 
      Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, 
      University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter 
      MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; 
      Judith Balmana, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas 
      Loman, Skanes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra 
      Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser 
      Research Center and Abramson Cancer Center, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Fielding, Anitra
AU  - Fielding A
AD  - Bella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; 
      Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana 
      Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, 
      Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute 
      of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; 
      Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of 
      Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer 
      Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, 
      University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter 
      MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; 
      Judith Balmana, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas 
      Loman, Skanes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra 
      Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser 
      Research Center and Abramson Cancer Center, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Domchek, Susan M
AU  - Domchek SM
AD  - Bella Kaufman and Ronnie Shapira-Frommer, Sheba Medical Center, Tel Hashomer; 
      Georgeta Fried, Institute of Oncology, Rambam Health Care Campus; Mariana 
      Steiner, Linn Medical Centre, Haifa; Salomon M. Stemmer, Rabin Medical Center, 
      Petah Tikva; Ayala Hubert, Hadassah-Hebrew University Hospital, Sharett Institute 
      of Oncology; Ora Rosengarten, Shaare Zedek Medical Centre, Jerusalem, Israel; 
      Rita K. Schmutzler, Center for Familial Breast and Ovarian Cancer and Center of 
      Integrated Oncology, Cologne, Germany; M. William Audeh, Samuel Oschin Cancer 
      Institute, Los Angeles, CA; Michael Friedlander, Prince of Wales Clinical School, 
      University of New South Wales, Sydney, New South Wales; Gillian Mitchell, Peter 
      MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; 
      Judith Balmana, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Niklas 
      Loman, Skanes Universitetssjuk Lund, Lund, Sweden; Karin Bowen and Anitra 
      Fielding, AstraZeneca, Macclesfield, United Kingdom; and Susan M. Domchek, Basser 
      Research Center and Abramson Cancer Center, University of Pennsylvania, 
      Philadelphia, PA. susan.domchek@uphs.upenn.edu.
LA  - eng
GR  - U24 CA078156/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
DEP - 20141103
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Antineoplastic Agents)
RN  - 0 (BRCA1 Protein)
RN  - 0 (BRCA1 protein, human)
RN  - 0 (BRCA2 Protein)
RN  - 0 (BRCA2 protein, human)
RN  - 0 (Phthalazines)
RN  - 0 (Piperazines)
RN  - WOH1JD9AR8 (olaparib)
SB  - IM
CIN - J Clin Oncol. 2015 Jan 20;33(3):229-31. PMID: 25452438
CIN - J Clin Oncol. 2015 Aug 10;33(23):2581-2. PMID: 26124473
CIN - J Clin Oncol. 2015 Aug 10;33(23):2582. PMID: 26124479
CIN - J Clin Oncol. 2015 Aug 10;33(23):2583-4. PMID: 26124483
CIN - Bull Cancer. 2019 Sep;106(9):717-718. PMID: 31420091
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - BRCA1 Protein/*genetics
MH  - BRCA2 Protein/*genetics
MH  - Breast Neoplasms/drug therapy/genetics
MH  - Disease-Free Survival
MH  - Drug Administration Schedule
MH  - Female
MH  - *Germ-Line Mutation
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*drug therapy/*genetics/pathology
MH  - Ovarian Neoplasms/drug therapy/genetics
MH  - Pancreatic Neoplasms/drug therapy/genetics
MH  - Phthalazines/administration & dosage/adverse effects/*therapeutic use
MH  - Piperazines/administration & dosage/adverse effects/*therapeutic use
MH  - Prospective Studies
MH  - Prostatic Neoplasms/drug therapy/genetics
MH  - Treatment Outcome
PMC - PMC6057749
MID - NIHMS653292
COIS- Authors' disclosures of potential conflicts of interest and author contributions 
      are found at the end of this article.
EDAT- 2014/11/05 06:00
MHDA- 2015/03/17 06:00
PMCR- 2014/11/03
CRDT- 2014/11/05 06:00
PHST- 2014/11/05 06:00 [entrez]
PHST- 2014/11/05 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
PHST- 2014/11/03 00:00 [pmc-release]
AID - JCO.2014.56.2728 [pii]
AID - 62728 [pii]
AID - 10.1200/JCO.2014.56.2728 [doi]
PST - ppublish
SO  - J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 
      Nov 3.